A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Stocks shrug off a new Trump tariff threat as the president-elect vows sweeping levies on the biggest U.S. trading partners.

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting ...

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

In cases involving unpredictable factors, such as most chemical reactions, pharmaceutical activity, and physiological ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

The Lebanese Army said it was deploying forces near the Israeli border as a U.S.-backed truce between Israel and Hezbollah militants began to take effect. Hamas is unlikely to compromise in Gaza ...